Search

Your search keyword '"Huvila, Jutta"' showing total 243 results

Search Constraints

Start Over You searched for: Author "Huvila, Jutta" Remove constraint Author: "Huvila, Jutta"
243 results on '"Huvila, Jutta"'

Search Results

3. Hormonal biomarkers remain prognostically relevant within the molecular subgroups in endometrial cancer

8. STING pathway expression in low‐grade serous carcinoma of the ovary: an unexpected therapeutic opportunity?

9. Endometrial Pipelle Biopsy Computer-Aided Diagnosis: A Feasibility Study

10. A platform for efficient establishment and drug-response profiling of high-grade serous ovarian cancer organoids

11. Classification of Vulvar Squamous Cell Carcinoma and Precursor Lesions by p16 and p53 Immunohistochemistry: Considerations, Caveats, and an Algorithmic Approach

12. Variability in endometrial carcinoma pathology practice: opportunities for improvement with molecular classification

13. Grade and Estrogen Receptor Expression Identify a Subset of No Specific Molecular Profile Endometrial Carcinomas at a Very Low Risk of Disease-Specific Death

14. Molecular subtype stratified outcomes according to adjuvant therapy in endometrial cancer

15. An immune score reflecting pro- and anti-tumoural balance of tumour microenvironment has major prognostic impact and predicts immunotherapy response in solid cancers

18. Importance of the criteria used for assessment of lymphovascular space invasion in endometrial carcinoma.

19. Variation in practice in endometrial cancer and potential for improved care and equity through molecular classification

24. The prognostic impact of the tumour stroma fraction: A machine learning-based analysis in 16 human solid tumour types

25. The cutoff for estrogen and progesterone receptor expression in endometrial cancer revisited: a European Network for Individualized Treatment of Endometrial Cancer collaboration study

28. Abstract PR002: Proteomic profiling of endometrial carcinomas

29. Addition of IMP3 to L1CAM for discrimination between low- and high-grade endometrial carcinomas: a European Network for Individualised Treatment of Endometrial Cancer collaboration study

30. Endometrial Pipelle biopsy computer-aided diagnosis (ENDO-AID): a feasibility study

33. Corrigendum to “Grade and Estrogen Receptor Expression Identify a Subset of No Specific Molecular Profile Endometrial Carcinomas at a Very Low Risk of Disease-Specific Death”: [Modern Pathology 36 (2023) 100085]

34. Abstract 6417: Deciphering aberrant STING pathway and exploring oncolytic viruses therapy in low grade serous ovarian carcinoma

35. Abstract 5779: A platform utilizing high-grade serous ovarian cancer organoids for prospective patient stratification in functional precision medicine

36. Supplementary figure 1 from Potential Targets' Analysis Reveals Dual PI3K/mTOR Pathway Inhibition as a Promising Therapeutic Strategy for Uterine Leiomyosarcomas—an ENITEC Group Initiative

37. Supplementary figure 2 from Potential Targets' Analysis Reveals Dual PI3K/mTOR Pathway Inhibition as a Promising Therapeutic Strategy for Uterine Leiomyosarcomas—an ENITEC Group Initiative

38. Supplementary figure 4 from Potential Targets' Analysis Reveals Dual PI3K/mTOR Pathway Inhibition as a Promising Therapeutic Strategy for Uterine Leiomyosarcomas—an ENITEC Group Initiative

39. Supplementary figure 3 from Potential Targets' Analysis Reveals Dual PI3K/mTOR Pathway Inhibition as a Promising Therapeutic Strategy for Uterine Leiomyosarcomas—an ENITEC Group Initiative

40. Supplementary methods from Potential Targets' Analysis Reveals Dual PI3K/mTOR Pathway Inhibition as a Promising Therapeutic Strategy for Uterine Leiomyosarcomas—an ENITEC Group Initiative

41. Supplementary data from Potential Targets' Analysis Reveals Dual PI3K/mTOR Pathway Inhibition as a Promising Therapeutic Strategy for Uterine Leiomyosarcomas—an ENITEC Group Initiative

43. Preoperative risk stratification in endometrial cancer (ENDORISK) by a Bayesian network model: A development and validation study

45. Relevance of Molecular Profiling in Patients With Low-Grade Endometrial Cancer

47. 37/#877 Hormonal biomarkers remain prognostic relevant within the molecular classification in endometrial cancer

49. Added Value of Estrogen Receptor, Progesterone Receptor, and L1 Cell Adhesion Molecule Expression to Histology-Based Endometrial Carcinoma Recurrence Prediction Models: An ENITEC Collaboration Study

50. The proteome of clear cell ovarian carcinoma

Catalog

Books, media, physical & digital resources